|Day Low/High||175.71 / 181.22|
|52 Wk Low/High||123.73 / 182.47|
Shire posted full-year profits that were largely in-line with analysts' forecasts and said it could see double-digit percentage growth in 2017 earnings per share.
The charts of these and two other big stocks are flashing warning signs at investors.
The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.
U.S. stock futures and shares in London and Asia fall Thursday after Donald Trump offers few details on his policies during his first press conference since winning the U.S. election.
European health care and pharmaceutical company shares were hit hard Thursday after President-elect Donald Trump accused some firms of 'getting away with murder' in his Wednesday press conference.
U.S. Patent Office allows Mylan to go after half a dozen patents tied to Allergan's dry eye franchise Restasis.
The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.
The Swiss biotech was last year reported to be a target of Shire.
Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?
Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.
The threat of a government clampdown on drug prices is off the table with Clinton's defeat, while wider support for defensive stocks helped push pharmaceuticals higher.
Stocks slip on Tuesday in a weaker start to November as uncertainty over the upcoming presidential election weighs on Wall Street.
Pfizer, Bayer, Shire are among rivals bracing for Roche's ACE910.
Wall Street suffered a dismal start to the month on Tuesday as conflicting polls bred uncertainty over the upcoming presidential election.
Stocks extend losses by mid-afternoon Tuesday in a weaker start to November as uncertainty over the upcoming presidential election weighs on Wall Street.
The German DAX leads the way as all major European indices close in the red on Tuesday.
The Federal Reserve will again convene in the coming week to discuss monetary policy, but investors will instead focus on what it may mean for a rate hike in December.
Why Trump is killing biotech stocks, the Shire-for-Radius rumor makes no sense and Bernie Sanders gets a tweeting lesson.
Given the biotech's growth prospects and pipeline assets, its shares seem greatly undervalued.
The Consumer Union is alleging that Mylan may have paid Teva to withhold its EpiPen competitor from the market.
When it comes to investing in health care, hedge fund pro John Paulson knows his stuff.
Stocks fluctuate on Monday as doubts over a production freeze agreement from major oil-producing countries snapped crude oil's recent rally.
Hedge fund managers continue to flee stocks in the second quarter, but the smart money eyed several potential opportunities, including Charter Communications and Morgan Stanley.
If they're underperforming, they're typically a precursor to a market correction.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.